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CONTAMINATION OF ANTI-VEGF DRUGS
FOR INTRAVITREAL INJECTION
How Do Repackaging and Newly Developed
Syringes Affect the Amount of Silicone Oil
Droplets and Protein Aggregates?
MARC SCHARGUS, MD,*† BENJAMIN P. WERNER, MSC,‡ GERD GEERLING, MD,*
GERHARD WINTER, PHD‡
Purpose: The particle counts and the nature of particles of three different antivascular
endothelial growth factor agents (VEGF) in different containers in a laboratory setting were
compared.
Methods: Original prefilled ranibizumab glass syringes, original vials with aflibercept,
and repacked ready-to-use plastic syringes with bevacizumab from a compounding
pharmacy and a compounding company (CC) were analyzed. Particle counts and size
distributions were quantified by different particle characterization methods (nephelometry,
light obscuration, Micro-Flow Imaging, nanotracking analysis, resonant mass measure-
ment). Using high-performance size-exclusion chromatography (HP-SEC), levels of protein
drug monomer and soluble aggregates were determined.
Results: Nearly all samples showed similar product quality. Light obscuration and Micro-
Flow Imaging showed a 4-fold to 9-fold higher total particle count in compounding
company bevacizumab (other samples up to 42,000 particles/mL). Nanotracking analysis
revealed highest values for compounding company bevacizumab (6,375 million particles/
mL). All containers showed similar amounts of silicone oil microdroplets. Ranibizumab
showed lowest particle count of all tested agents with only one monomer peak in HP-SEC.
Repackaged bevacizumab from different suppliers showed varying product quality.
Conclusion: All three tested agents are available in similar quality regarding particulate
purity and silicone oil microdroplet count. Repackaging can have a major impact on the quality.
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Intravitreal antivascular endothelial growth factor(VEGF) agents, including ranibizumab (Lucentis;
Genentech, San Francisco, CA), bevacizumab
(Avastin; Genentech) and aflibercept (Eylea; Regeneron
Pharmaceuticals, Inc, Tarrytown, NY), are used for
years to treat several kinds of retinal vascular
disorders.1–3 Short-term and transient intraocular pres-
sure (IOP) rise is well known to occur after intravitreal
injection and is easy to explain because of injection of
the fluid volume into the vitreous with the different
anti-VEGF agents.4,5 Long-term or sustained IOP rise
has a more difficult mechanism and has been reported
clinically in several case reports and case series. Bakri
et al6 first reported sustained IOP rise after ranibizu-
mab injections requiring medical treatment in a small
series of four patients and Kahook et al reported
similar findings in six patients.7 Several studies with
different number of patients followed reporting prev-
alence of long-term IOP rise after treatment with rani-
bizumab, bevacizumab, or aflibercept injections.7–20
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Recent retrospective analysis of the VIEW 1 and
2 data of 2,457 patients showed significant higher IOP
elevation in ranibizumab than in aflibercept injected
eyes.21 This study showed for the first time in a high
number of patients a statistically significant IOP ele-
vation difference between these two agents. Notably
all studies evaluating IOP elevations after anti-VEGF
injections are limited because of the retrospective
design of the analysis.
Several mechanisms have been proposed to explain
clinically significant IOP elevation after anti-VEGF
treatment. Such mechanisms include mechanical
trauma to the trabecular meshwork from repeated
injection-related IOP spikes and a decrease in aqueous
outflow because of VEGF blockade, as potentially
mediated by inhibition of nitric oxide synthesis, or
inflammation or obstruction by high molecular weight
protein aggregates or silicone microdroplets.22–24
Because of the different size of molecules (bevacizu-
mab has a molecular weight of 149 kDa, aflibercept of
115 kDa, and ranibizumab of 48 kDa), it has been
assumed that the agents can accumulate in the trabec-
ular meshwork especially after long-term repeated
administration and cause either direct obstruction or
indirect change of the outflow facility. Other proposed
mechanisms postulate outflow obstruction by protein
aggregates and/or silicone oil droplets from the syrin-
ges or needles used.24–26 Liu et al reported both
protein aggregates and particles $1 mm in repackaged
bevacizumab obtained from three external compound-
ing pharmacies in the United States.26
All three agents are currently prepared and distrib-
uted in different containers. Ranibizumab comes in
two possible injection containers. First, there is
a single-dose vial, which is drawn into a syringe
immediately before injection. Second, since 2013,
there is a prefilled syringe available in the European
Union, which has been approved also by the U.S.
Food and Drug Administration (FDA) in 2016.
Currently, mainly the prefilled syringe is used in
central Europe.27,28 Aflibercept is only delivered in
a single-dose vial, which is drawn into a syringe
immediately before injection. The use of bevacizumab
as intravitreal agent is off-label. Bevacizumab is there-
fore only available from compounding pharmacies as
an agent drawn from a larger vial and then usually
filled into multiple syringes, which are stored in
a refrigerator at 2°C to 8°C before use.26 Theoretically,
this compounding, refilling, inadvertent freeze and
thaw processes carries an increased risk for aggregate
and particle generation.
Liu et al quantified levels of subvisible particles and
protein aggregates in repackaged bevacizumab syrin-
ges obtained from compounding pharmacies, as well
as in samples of bevacizumab and ranibizumab vials
tested in controlled laboratory experiments.25 The
ready-to-use prefilled ranibizumab was not available
at the time of Liu’s publication.
Aim of this study was to add further laboratory data
on levels of subvisible particles and protein aggregates
in a new prefilled ranibizumab syringe product and in
the aflibercept product and to compare it to samples
of bevacizumab delivered from a compounding
pharmacy and from a compounding company.
Materials and Methods
Materials
The products of interest were bevacizumab 25 mg/mL,
repackaged by the central pharmacy of the University
Hospital Duesseldorf in 1 mL Braun syringes with
a volume of 150 mL (8 units; Avastin Roche 3.75 mg;
batch No. B8008H10) (bevacizumab D), bevacizumab
25 mg/mL, repackaged by BA.Herstellung GmbH &
Co. KG in a Braun micro-fine insulin syringe U100
with a 30G staked-in needle with a volume of 50 mL
(16 units; Avastin Roche 3.75 mg; batch No.
060117APO) (bevacizumab F), original aflibercept
40 mg/mL supplied in a vial and with a 5-mm filter
needle (6 units; EYLEA 40 mg/mL injection solution
in a vial, Bayer; batch No. 54269C) and original rani-
bizumab 10 mg/mL in a siliconized glass syringe
(6 units; Lucentis 10 mg/mL injection solution in a pre-
filled syringe; Novartis; batch No. S2050C). All units
were packed in shock absorbing containers with
cooling packs until arrival at the laboratory of the
Department of Pharmacy, Pharmaceutical Technology
and Biopharmaceutics at the Ludwig-Maximilians-
University in Munich. Upon arrival, all products were
visually inspected for any damages. No damages and
no signs of freezing were detected. Samples were
stored light protected at 6°C in the middle of a refrig-
erator to prevent any impact of light or freeze-thawing
effects until direct analysis.
Sample Preparation
All steps like extracting the protein solution from
the product container, sample dilution, or aliquoting
was carried out under a laminar flow hood according
to aseptic handling. For the simulation of a real
application, all products were prepared according to
the manufacturer instructions. An exception of this
was that the whole syringe content was used instead of
disposing some of the protein solution as instructed to
avoid wasting product volume, which was required for
analysis. Briefly, aflibercept solution was aspirated
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from the vial with the enclosed 18G · 1 ½ BD Blunt
Fill Needle 2 Filter (Becton, Dickinson and Company
Limited, Franklin Lakes, NJ) into a BD 1-mL syringe
with Luer-Lok Tip (Becton, Dickinson and Company
Limited). The filter needle was removed. The follow-
ing procedure was now the same as for the other two
products, bevacizumab D and ranibizumab. A 30G ½99
BD Microlance 3 (Becton, Dickinson and Company
Limited, Drogheda, Ireland) was attached to the
syringe and the protein solution was expelled into
a 50-mL Greiner tube. The repackaged bevacizumab
F was stored in Braun micro-fine insulin syringes
U100 with a staked-in needle. In this case, the product
was directly expelled into the tube. All aliquots of the
same product were pooled in one tube. For analysis,
the pooled samples were diluted 1:20 in the appropri-
ate formulation buffer. The buffers were filtered before
with a medical polyethersulfone filter with a pore size
of 0.2 mm (Pall PharmAssure; Pall GmBH, Dreieich,
Germany) before the addition of the concentrated
protein solution. The samples were analyzed within
three days after dilution. The presented data show
the calculated results for nondiluted samples except
for nephelometry where the results of the diluted
samples are presented. Particle analysis was performed
on calibrated equipment. Duke Standards and Count-
Cal Particle Size Standards were used (both Thermo
Scientific, Fremont, CA).
Methods
Nephelometry. A Nephla turbidimeter (Dr. Lange,
Düsseldorf, Germany) was used to determine the
turbidity of the samples. At an angle of 90°, scattered
light from a laser with a wavelength of 860 nm is
detected. Triplicate measurements were performed
and presented in the form of formazin nephelometric
units (FNU).
Light obscuration. Light obscuration was performed
by using a SVSS-C device from PAMAS GmbH and
the software PAMAS PMA Program V 2.1.2.0
(Rutesheim, Germany) for the quantification of
particles in the subparticle and visible particle range.
The system cleanliness was tested before each sample
by measuring the particle content of highly purified
water. Each sample run was carried out in triplicates of
0.3 mL after a prerun of 0.4 mL. Each sample was
analyzed in triplicates resulting in a total of nine single
runs. The speed for the aspiration of the solution was
set to 10 mL/minute.
High-performance size-exclusion chromatography.
For the evaluation of the relative amount of soluble
protein species, size exclusion chromatography
(HP-SEC) was carried out. A flow of 0.5 mL/minute
with a mobile phase consisting of 300 mM sodium
chloride and 50 mM phosphate pH 7 in highly purified
water was applied on a TSKgel 3000SWXL column
(Tosoh Bioscience GmbH, Stuttgart, Germany). Sam-
ples were centrifuged before analysis for 10 minutes at
14,000 rpm. Twenty-five microliters of the diluted
protein solution were injected. Each product was run
six times. Analysis was carried out on a Waters 2695
Alliance Separation Module (Waters Corporation,
Milford, MA) with a Waters 2487 Dual l Absorbance
Detector for UV absorbance at 280 nm. Data analysis
was carried out with Chromeleon V6.8.
Micro-Flow Imaging. A Micro-Flow Imaging DPA
4100 device (BrightWELL Technologies Inc, Ottawa,
Canada) with a 100-mm flow cell in the operation
mode high magnification was used. The software
MFI Particle Analyzer V6.9.7.2 was applied for anal-
ysis. The flow cell was flushed with highly purified
water and flow cell cleanliness was checked between
each run. The cell was flushed with 0.5 mL of the
corresponding buffer to optimize illumination, which
ensures a correct system thresholding, before each
analysis. Next, the cell was loaded with 0.3 mL before
0.65 mL of the sample was analyzed at a flow rate
of 0.1 mL/minute. Triplicate measurements were
performed.
Nanotracking analysis. A NanoSight LM20
(NanoSight, Amesbury, United Kingdom) with the
software NTA 2.3 was used for capturing the particle
movement in the nanometer range for 60 seconds. The
camera shutter and gain were set to 1,497 and 680,
respectively. The sample cell was flushed with highly
purified water before it was loaded air bubble free
with 0.5 mL sample. Between each analysis of the
triplicate, 0.1 mL sample was loaded into the cell.
Loading was performed with a 1-mL Terumo Syringe
without needle (Terumo (Philippines) Corporation,
Laguna, Philippines). During video capture, no flow
was applied.
Resonant mass measurement. For the differentiation
of protein and silicone oil particles in a particle size
range from 300 nm to 5 mm, resonant mass measure-
ment with a Hi-Q Micro Sensor was carried out (Affin-
ity Biosensors LLC, Santa Barbara, CA). Before the
sample was loaded for 40 seconds, the sensor was
flushed with highly purified water. Next, in the auto-
matic limit of detection mode, the limit of detection
was determined three times before calculating the
mean value. The mean value was then used for
the measurement. Analysis was stopped either after
the volume reached 150 nL or 10 minutes. The manual
stop needed to be performed because of very low
particle counts in the samples leading to a wrongly
recognized analysis volume. The density of protein
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particles was set to 1.32 g/mL and for silicone oil to
0.97 g/mL. The software ParticleLab V 1.9 (Affinity
Biosensors LLC) was used for analysis. Each product
was measured three times.
Results
Nephelometry
The determination of the opalescence of the buffer
and protein solutions showed for all samples very low
values (Figure 1). The addition of the protein solutions
to the corresponding filtered placebo buffers led to
a slight increase of the turbidity. One reason for the
slightly lower opalescence value for the diluted rani-
bizumab samples in comparison with the other three
products is the lower concentration of ranibizumab by
a factor of 2.5 and four to bevacizumab and aflibercept,
respectively. Overall, the samples were clear and no
particles visible.
Light Obscuration and Micro-Flow Imaging
The particle burden in the subvisible range was
measured with light obscuration and Micro-Flow
Imaging (Table 1). The filtered placebo buffer solu-
tions contained only a minor amount of particles
(,1,100 particles [$1 mm]/mL), whereas all protein
solutions, except bevacizumab F, showed a (calculated)
particle level in a range of around 36,000 to 42,000
particles ($1 mm)/mL. Bevacizumab F displayed
particle counts by a factor of at least four (light obscu-
ration) and nine (Micro-Flow Imaging) higher than the
other samples. Ranibizumab had the overall lowest
particle count. The difference in the solutions with
and without protein clearly demonstrated the presence
of many small protein and silicone oil particles in the
product solutions. Particles larger than 10 mm as well
as 25 mm were on a low level, if existing at all.
Nanotracking Analysis
Measuring submicrometer particles with nanotrack-
ing analysis revealed a particle level of up to 102
million particles/mL for all placebo buffers (Figure 2).
In comparison, highly purified water had a particle
count of around 12 million particles/mL. In the protein
samples, however, hundreds of millions of particles in
the low nanometer range were detected. The highest
value with 6,375 million particle/mL was obtained for
bevacizumab F, followed by aflibercept with 4,082
million particles/mL. The high particle count observed
for aflibercept can be attributed to the highest protein
concentration. Bevacizumab D showed less than half
the number and ranibizumab showed about one-fourth
of the number of submicroparticles compared with
aflibercept. The mean particle size for all drug samples
Fig. 1. Nephelometry data for buffers and diluted (1:20) protein
solutions.
Table 1. The Total Particle Count (Particles $1 mm, Calculated After Measuring Samples With 1:20 Dilution) of Each
Sample as Determined by Light Obscuration and Micro-Flow Imaging is Listed
Light Obscuration Micro-Flow Imaging
Particles/mL $ Particles/mL $
1 mm 10 mm 25 mm 1 mm 10 mm 25 mm
Bevacizumab D buffer 546 ± 7 13 ± 6 7 ± 5 54 ± 23 0 0
Bevacizumab D 41,733 ± 9,374 622 ± 212 82 ± 122 42,848 ± 12,097 535 ± 463 0
Bevacizumab F buffer 81 ± 6 3 ± 3 0 498 ± 58 7 ± 13 0
Bevacizumab F 182,919 ± 2,168 2,126 ± 151 37 ± 46 414,308 ± 40,781 2,663 ± 3,107 0
Aflibercept buffer 1,049 ± 41 6 ± 4 1 ± 1 255 ± 47 0 0
Aflibercept 36,096 ± 5,356 163 ± 100 7 ± 13 44,299 ± 4,244 271 ± 470 0
Ranibizumab buffer 1,093 ± 95 5 ± 1 0 121 ± 70 0 0
Ranibizumab 37,755 ± 14,715 570 ± 490 82 ± 90 19,815 ± 9,358 267 ± 463 0
The table further contains the particle numbers of interest regarding the USP requirements (particles $ 10 mm and particles $ 25 mm).
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was around 184 nm ± 21 nm. Aflibercept and ranibi-
zumab nanoparticles had a similar mean particle diam-
eter of 163 nm ± 10 nm and 171 nm ± 35 nm, whereas
bevacizumab D and bevacizumab F particles showed
a broader distribution and a larger mean value of
192 nm ± 62 nm and 209 nm ± 11 nm, respectively.
Resonant Mass Measurement
For the differentiation of silicone oil and protein
particles, resonant mass measurement was performed
(Figure 3). Overall, the particle burden of all solutions
was very low and near the detection limit because of
the high cleanliness of the samples. For comparison,
highly purified water had a particle burden of around
50,000 particles ($0.3 mm)/mL and a buffer showed
values of 400,000 particles ($0.3 mm)/mL. In all
cases, silicone oil droplets were detected beside pro-
tein particles. The particle numbers were similar for
bevacizumab D, bevacizumab F and aflibercept; rani-
bizumab showed a much smaller overall particle
number. For bevacizumab D, bevacizumab F and
aflibercept, a relatively small amount of silicone oil
in comparison with the amount of protein particles
was found. Silicone oil droplets are more dominant
for ranibizumab, which is stored in a siliconized glass
syringe and has an overall lower protein content.
High-performance Size-exclusion Chromatography
Bevacizumab D and F showed similar shares of
soluble protein species as detected with HP-SEC
(Figure 4). One peak represented the monomer,
whereas the other ones represented dimers and higher
molecular weight protein species. Tiny amounts of
higher molecular weight protein species made a per-
centage of around 0.1%, whereas the monomer
accounted for around 98.2% and the dimers for
roughly 1.7%. Two peaks were found for aflibercept,
representing the monomer and higher molecular
species with a share of 98.8% and 1.2%, respectively.
For ranibizumab, only a monomer peak was detected.
Discussion
Intravitreal injection of anti-VEGF drugs can lead to
an increased long-term IOP.4,5,7–20 Several mecha-
nisms to explain this phenomenon including the pos-
sibility that protein aggregates and silicone oil
microdroplets are responsible for the IOP elevation
are discussed.22–24 Protein aggregates can be formed
Fig. 2. The total (calculated) particle count/mL of all nanometer par-
ticles is displayed for each sample as determined by nanotracking
analysis.
Fig. 3. The (calculated) cumulative particle count/mL of silicone oil and
protein particles is shown as determined by resonant mass measurement.
Fig. 4. Determination of the relative amount of protein species for
different anti-VEGF drugs with HP-SEC.
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by various pathways, including temperature, light,
freeze-thawing or shaking during drug transportation
and handling or just by long-term storage.25,29 The
major source for silicone oil particles is the primary
packaging container of the drug substance. Other sour-
ces could be silicone-oil-coated stoppers, the syringe
used for drug aspiration or the needles used for
withdrawing or injection of the drug.
Obstruction of the outflow pathway by particulate
matter with IOP elevation is a well-known phenome-
non in experimental glaucoma models.30
To the best knowledge of the authors, this is the first
study directly comparing subvisible particle numbers
and type in all three clinically used anti-VEGF drugs
in the current application form.
In this study, the level and nature of the particles
found in anti-VEGF drugs for intravitreal injection
were identified and quantified.
The diluted samples showed no sign of visible
particles before analysis, which was confirmed by low
nephelometry data (Figure 1) and overall moderate-to-
low particle counts for all products except bevacizu-
mab F (Table 1). Eventually, the high particle count in
bevacizumab F in comparison with the agents could be
explained by the primary packaging material. For
expelling the protein solution, an external 30G needle
was attached to the syringe for all agents beside bev-
acizumab F. Bevacizumab F was supplied with
a staked-in needle syringe. In another intravitreal
injection study, intravitreal silicone oil droplets were
more often detected with staked-in needle syringes
than with luer cone syringes with an attached needle.
The explanation of the authors was that a 50-mL resid-
ual space is present in the needle hub for attached
needles. For staked-in needles, this space is missing.
In this space, silicone oil, which was scratched off the
syringe barrel during ejection, can accumulate and is
not injected into the eye, whereas it is in the staked-in
needle syringe.31 This hypothesis is supported by
observations during preparation of this study. The loss
of volume was higher for bevacizumab D; whereas in
case of bevacizumab F, the complete small volume of
50 mL could be expelled. Other factors playing a role
in the higher particle count of bevacizumab F could be
the product itself or handling during storage, repack-
aging, or transportation. For ranibizumab, one should
keep in mind that it has a 2.5, respectively, 4-fold
lower protein concentration than the other products
and the overall lower particle counts can in part be
explained by that. Despite moderate-to-low particle
counts in three out of four products, it is notable that
all investigated products would theoretically not meet
the specifications by U. S. Pharmacopeial Convention
reference standard (USP) 789 (Table 1).32 USP 789
deals with the foreign particulate matter in
ophthalmic solutions and requires a particle count below
50 particles/mL$ 10 mm, 5 particles/mL$ 25 mm and
2 particles/mL $ 50 mm,32 respectively. It has to be
mentioned that our measurements were performed
according to USP 787, not according to USP 788 (as
it is normally required in USP 789).32–34 USP 787 differs
from USP 788 mainly by the analyzed volume. USP 787
is designed for therapeutic protein injections with low
volumes and can be performed with 0.2 mL to 0.5 mL,
whereas USP 788 would require a volume of 25 mL.
The particle number limits are the same for USP 787 and
USP 788.33,34 The filtered aflibercept shows the best
values regarding these requirements, although it would
not meet them. Similar findings were already reported by
Palmer et al and Yannuzzi et al.35,36 They found in
repackaged as well as in original bevacizumab particle
counts higher than the limits set by the pharmacopoeia.36
A future solution to reduce particle numbers and to fulfill
the requirements by the USP might be to filter the pro-
tein solutions before administration with a lower pore
size filter (e.g., 0.2 mm).37 Further, a batch-to-batch var-
iation cannot be excluded because all our samples
derived from one batch. Such a variation is possible as
several other reports show.25,35,36,38 Particle levels do
not only vary between different compounders but may
even vary between syringes produced from the same
original vial content.25,26,36 Analyzed samples from this
study were taken from standard clinical settings and
therefore reflect real live anti-VEGF samples for
injections in patients.
So far, only Micro-Flow Imaging data are published
to quantify silicone oil and protein particles in
ophthalmic preparations.25 A drawback of this method
is that a reliable differentiation is only possible at par-
ticle sizes over 5 mm. Because smaller particles might
have an effect on the trabecular meshwork, resonant
mass measurement was applied. With this technique,
also the nanometer range can be analyzed. The analy-
sis revealed millions of nanometer-ranged silicone oil
and protein particles (Figure 3). But, overall the
samples contain a low amount of silicone oil and the
absolute amount is similar for all four products in
the study. The total particle number measured with
resonant mass measurement is clearly lower for rani-
bizumab. The contribution of silicone oil microdrop-
lets to the overall particle level in repackaged
bevacizumab samples has been shown several
times.25,38 It was observed that the amount of silicone
oil has not changed much over the investigated period
of several weeks for nearly all tested samples.25,36,38
Nevertheless, the particle burden in repackaged beva-
cizumab increased over time,25,36 suggesting protein
aggregation, beside silicone oil as cause for the
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particle elevation.36 Otherwise, bevacizumab seems to
be stable for several weeks in repackaged
syringes.25,36,38,39
Nanotracking analysis measurements revealed a high
amount of nanosized particles (Figure 2) and
confirmed the overall particle number trends gained
by light obscuration and MFI (Table 1).
For the identification of the amount of soluble
protein aggregates, HP-SEC was carried out (Figure
4). Overall, the data correlate well with the findings
for the insoluble particles. In accordance with litera-
ture, bevacizumab contains a small percentage of
higher molecular weight species. The investigated
bevacizumab samples had an amount of roughly
1.8%, whereas others detected a value of 1.56%38 or
even higher.25,40 Besides the monomer peak, a protein
dimer peak was observed as well for aflibercept in
a low concentration of 1.2% of the total protein
concentration. The higher molecular species peak
was so far not described in literature.41 The detection
of only the ranibizumab monomer peak with HP-SEC
was in accordance with literature.40
Several authors have postulated mechanisms
explaining long-term IOP elevation after repeated
anti-VEGF injections.6,7,10,25 Most mechanisms refer
to mechanic or postinflammatory occlusion of the
trabecular meshwork outflow pathway. None of these
mechanisms have been proved so far, possibly reasons
are multifactorial. Direct toxic effects have been
examined as well; but even in much higher doses than
clinically used, there is no toxic effect of anti-VEGF
agents in laboratory setting.42
Conclusion
Summarizing, the product quality of the repackaged
bevacizumab D, the aflibercept vial, and the new
siliconized glass syringe ranibizumab is overall
similar. Repackaged bevacizumab F shows a much
higher particulate burden, particularly when the stan-
dard method of light obscuration is applied. This
might be due to the fact that a staked-in needle syringe
was used in contrast to the other products, but also
other reasons cannot be excluded. Ranibizumab dis-
plays in the majority of the applied analytical methods
the highest quality with regard to protein-based sub-
micron particles. However, one should keep in mind
that protein concentration in ranibizumab is the lowest
one. At least with the new syringe-packaged ranibi-
zumab product, differences to aflibercept like they
were hypothesized in the VIEW 1 and 2 study could
no longer be correlated with high particle burden in
future use. Further, it can be stated that repackaging in
general does not lead to inferior quality regarding
particulate levels compared with “original” products.
But already with only two repackaged bevacizumab
products in hand, relevant differences could be
detected. With only one batch of repackaged bevaci-
zumab F at disposal, it is impossible to judge the cause
for its inferior performance in comparison with the
other investigated samples. When it comes to larger,
two digit micrometer-sized particles application of a fil-
ter (needle) like for aflibercept appears helpful,
although such a filter does not reduce smaller particles.
In summary, it is important to make clear that none
of the investigated three agents stood out in terms of
particulate impurity. We found high numbers of
submicron particles with different analytical methods.
The relevance of such particles is still unclear, nor do
we have specifications, or an industry standard for
quantifying them. Therefore, caution has to be applied
before drawing conclusions. Yet, in the context of the
ophthalmic use of protein drug products and the
clinical experience with elevated IOP, it appears
urgent to put more effort into research correlating
these factors.
Key words: aflibercept, bevacizumab, contamina-
tion, intraocular pressure, protein particles, ranibizu-
mab, silicone oil.
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